Jihong Chen

Dr. Jihong Chen

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2025 in Maritime Policy & Management
Verified
Journal Article
Closed access
Bingmei GuBingmei Gu
Bingmei Gu
JCJihong Chen
Jihong Chen
Professor Hercules HaralambidesProfessor Hercules Haralambides
Professor Hercules Haralambides
Jiaguo LiuJiaguo Liu
Jiaguo Liu

20 June 2023 in Frontiers in Public Health
Verified
Journal Article
Open access
JLJi Lecai
Ji Lecai
PMPeierdun Mijiti
Peierdun Mijiti
HCHong Chuangyue
Hong Chuangyue
QGQian Gao
Qian Gao
TWTan Weiguo
Tan Weiguo
JCJihong Chen
Jihong Chen
Background: WHO recommended multidrug-resistant tuberculosis (MDR-TB) should be treated mainly under ambulatory model, but outcome of ambulatory treatment of MDR-TB in China was little known.Methods: The clinical data of 261 MDR-TB patients treated as outpatients in Shenzhen, China during 2010–2015 were collected and analyzed retrospectively.Results: Of 261 MDR-TB patients receiving ambulatory treatment, 71.1% (186/261) achieved treatment success (cured or completed treatment), 0.4% (1/261) died during treatment, 11.5% (30/261) had treatment failure or relapse, 8.0% (21/261) were lost to follow-up, and 8.8% (23/261) were transferred out. The culture conversion rate at 6 months was 85.0%. Although 91.6% (239/261) of patients experienced at least one adverse event (AE), only 2% of AEs caused permanent discontinuation of one or more drugs. Multivariate analysis showed that previous TB treatment, regimens containing capreomycin and resistance to FQs were associated with poor outcomes, while experiencing three or more AEs was associated with good outcomes.Conclusion: Good treatment success rates and early culture conversions were achieved with entirely ambulatory treatment of MDR-TB patients in Shenzhen, supporting WHO recommendations. Advantageous aspects of the local TB control program, including accessible and affordable second-line drugs, patient support, active monitoring and proper management of AEs and well-implemented DOT likely contributed to treatment success rates.

25 October 2024 in Analytical Chemistry
Verified
Journal Article
Closed access
WMWenjie Ma
Wenjie Ma
TXTingfei Xie
Tingfei Xie
JLJinyan Li
Jinyan Li
ZWZhitao Wang
Zhitao Wang
PZPengfei Zhang
Pengfei Zhang
JCJihong Chen
Jihong Chen

15 September 2023 in Microchimica Acta
Verified
Journal Article
Closed access
PDF file
YXYunpeng Xu
Yunpeng Xu
JCJiahui Chen
Jiahui Chen
XSXiaolu Sui
Xiaolu Sui
YZYanzi Zhang
Yanzi Zhang
AZAisha Zhang
Aisha Zhang
JCJihong Chen
Jihong Chen

1 January 2023 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
XSXiaolu Sui
Xiaolu Sui
TXTingfei Xie
Tingfei Xie
YXYunpeng Xu
Yunpeng Xu
AZAisha Zhang
Aisha Zhang
YZYanzi Zhang
Yanzi Zhang
JCJihong Chen
Jihong Chen
Interstitial inflammation is an important mechanism of pathological damage in renal injury caused by hyperuricemia. Protease-activated receptor-2 (PAR2) is a class of targets that act upstream of the PI3K/AKT/NF-κB pathway and is involved in various inflammatory diseases. We induced a hyperuricemia model in rats by adenine and ethambutol gavage in an in vivo experiment. We demonstrated that PAR2 and PI3K/AKT/NF-κB pathway expression were significantly upregulated in renal tissues, with massive inflammatory cell infiltration in the renal interstitium and renal tissue injury. Treating hyperuricemic rats with AZ3451, a selective metabotropic antagonist of PAR2, we demonstrated that PAR2 antagonism inhibited the PI3K/AKT/NF-κB pathway and attenuated tubular dilation and tubulointerstitial inflammatory cell infiltration. The phospholipid metabolism profiles provided a perfect separation between the normal and hyperuricemic rats. In addition, we also found that AZ3451 can affect phospholipid metabolism. Our work suggests that PAR2 may mediate hyperuricemia-mediated renal injury by activating the PI3K/AKT/NF-κB pathway. The PAR2 antagonist AZ3451 may be a promising therapeutic strategy for hyperuricemia-induced inflammatory responses.

12 June 2022 in Cardiovascular Therapeutics
Verified
Journal Article
Open access
PDF file
TXTingfei Xie
Tingfei Xie
YXYunpeng Xu
Yunpeng Xu
LJLecai Ji
Lecai Ji
XSXiaolu Sui
Xiaolu Sui
AZAisha Zhang
Aisha Zhang
JCJihong Chen
Jihong Chen
Purpose. An arteriovenous fistula (AVF) is the preferred vascular access mode for maintenance hemodialysis, and access stenosis and thrombosis are the primary causes of AVF dysfunction. This study is aimed at exploring the molecular mechanisms underlying AVF development and the roles of the heme oxygenase 1/peroxisome proliferator-activated receptor gamma (HO-1/PPAR-γ) pathway in AVF. Method. AVF model mice were established, and the vascular tissues from the arteriovenous anastomosis site were sent for mRNA sequencing. Differentially expressed mRNAs (DEmRNAs) were screened and subjected to functional analysis. Thereafter, the mice with HO-1 knockdown and coprotoporphyrin IX chloride (COPP) pretreatment were used to investigate the roles of the HO-1/PPAR-γ pathway in AVF. Results. By sequencing, 2514 DEmRNAs, including 1323 upregulated and 1191 downregulated genes, were identified. These DEmRNAs were significantly enriched in the PPAR signaling pathway, AMPK signaling pathway, glucagon signaling pathway, IL-17 signaling pathway, and Toll-like receptor signaling pathway. High expression of HO-1 and PPAR-γ reduced endothelial damage and intimal hyperplasia during AVF maturation. After AVF was established, the levels of transforming growth factor-β (TGF-β), interleukin-1β (IL-1β), interleukin-18 (IL-18), and reactive oxygen species (ROS) were significantly increased ( ), and HO-1 normal expression and COPP pretreatment evidently decreased their levels in AVF ( ). Additionally, AVF significantly upregulated HO-1 and PPAR-γ and downregulated MMP9, and COPP pretreatment and HO-1 normal expression further upregulated and downregulated their expression. Conclusion. The HO-1/PPAR-γ pathway may suppress intimal hyperplasia induced by AVF and protect the intima of blood vessels by regulating MMP9 and ROS, thus mitigating AVF dysfunction.